

Standard declaration of interests (DOI) form for individuals applying to be appointed as members or experts of Scientific Committees and their Working Groups in a personal capacity

Legal basis:

Commission Decision C(2015)5383 on establishing Scientific Committees in the field of public health, consumer safety and the environment, Article 16, and Commission Decision C(2016)3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 11.

Definitions:

"Conflict of interest" means any situation where an individual has an interest that may compromise or be reasonably perceived to compromise the individual's capacity to act independently and in the public interest when providing advice to the Commission in relation to the subject of the work performed by the Scientific Committees and their working groups in question.

"Immediate family member" means the individual's spouse, children and parents. "Spouse" includes a partner with whom the individual has a registered non marital regime. "Children" means the child(ren) the individual and the spouse have in common, the own child(ren) of the individual and the own child(ren) of the spouse.

"Legal entity" means any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

"Body" means a governmental, international or non-profit organisation.

"Meeting" includes a series or cycle of meetings.

Please answer each of the questions below. If the answer to any of the questions is "yes", please briefly describe relevant interests and circumstances, as appropriate.

If you do not describe relevant interests, your DOI form will be considered incomplete and, therefore, your application to be appointed as a member of an expert group or subgroup in a personal capacity shall be rejected.

First name: Peter

Family name: Hoet

Expert group/sub-group: SCHEER / SCCS WG Nano in cosmetics

1 EMPLOYMENT CONSULTANCY AND LEGAL REPRESENTATION

	<i>Within the past 5 years, were you employed or have you had any other professional relationship with a natural or legal entity, or held any non-remunerated post in a legal entity or other body with an interest in the field of activity of the Scientific Committees and their working groups in question?</i>	yes	no
--	---	------------	-----------

1a	Employment	<input checked="" type="checkbox"/>	<input type="checkbox"/>
1b	Consultancy, including services as an advisor	<input type="checkbox"/>	<input checked="" type="checkbox"/>
1c	Non-remunerated post	<input type="checkbox"/>	<input checked="" type="checkbox"/>
1d	Legal representation	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Activity	Time period (from... until month/year)	Name of entity or body	Description
Employment	10/1989 - now -	Name: Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgie; Catholic University Leuven, Leuven, Belgium	KU Leuven - University Department of Public Health; Social and Preventive Health Care; Occupational, Environmental and Insurance Medicine Our University and our unit has no official responsibility to carry out risk management My tasks at the University - Teaching: courses related to toxicology, toxicity testing and environment and health - Research: Occupational, Environmental and Insurance Medicine - Unit Experimental Toxicology

2 MEMBERSHIP OF MANAGING BODY, SCIENTIFIC ADVISORY BODY OR EQUIVALENT STRUCTURE

	<i>Within the past 5 years, have you participated in the internal decision-making of a legal entity or other body with an interest in the field of activity of the Scientific Committees and their working groups in question or have you participated in the works of a Scientific Advisory Body with voting rights on the outputs of that entity?</i>	yes	no
--	---	------------	-----------

2a	Participation in a decision-making process	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2b	Participation in the work of a Scientific Advisory Body	<input checked="" type="checkbox"/>	<input type="checkbox"/>

Activity	Time period (from... until month/year)	Name of legal entity or body	Description
2 a Member of a Scientific Advisory Body or equivalent structure	01/2004 – now	Belgian Society of Toxicology and Ecotoxicology, abbreviated as BelTox, Brussels, Belgium EC.	Board member It is the objective of BelTox to improve the practices in hazard and risk assessment of chemicals in Belgium by promoting the regular exchange of science among students and professionals from scientific institutions, universities, authorities, industry and consulting companies in the fields of toxicology and ecotoxicology. The statutes of the Belgian Society of Toxicology (Société belge de toxicologie, Belgische vereniging voor toxicologie, BelTox) were published in the “Moniteur belge, Belgisch staatsblad” of 15-06-1989, N 007154. No of the Society: 715489 Enterprise no: 439308941 http://toxsoebe.webhosting.be/about-belttox/
2b. Member of a Managing Body, Scientific Advisory Body or equivalent structure	02/2009 - 2016	Public Health and Risk Assessment, EC.	Member of the Scientific Committee on Emerging and New Identified Health Risks (SCENIHR) Directorate C - Public Health and Risk Assessment, EC. During the plenary meetings of the SC all opinions etc are discussed and approved. I was also a member of the following WP preparing specific opinions: - Addictiveness and Attractiveness of Tobacco Additives - Memorandum on the use of the scientific literature for human health risk assessment purposes - weighing of evidence and expression of uncertainty - The safety of Metal-on-Metal joint replacements with a particular focus on hip implants

			<p>- Nanosilver: safety, health and environmental effects and role in antimicrobial resistance http://ec.europa.eu/health/scientific_committees/emerging/index_en.htm</p>
2b Member of a Managing Body, Scientific Advisory Body or equivalent structure	01/2013 - now	- Scientific Committee of the Federal Agency on Food Safety (FAVV), Brussels, BE	<p>The Scientific Committee has a central role in the assessment of the risks in terms of the food chain. It consists of scientists who specialize in this field. If necessary, it can be relied on a network of experts when very specific problems arise.</p> <p>http://www.afsca.be/wetenschappelijkcomite/leden.asp</p>
2b Member of a Managing Body, Scientific Advisory Body or equivalent structure	01/2005 - now	Ad hoc member of Scientific Committee on Consumer Safety (SCCS) Public Health and Risk Assessment, EC.	<p>The Committee provides opinions on health and safety risks (chemical, biological, mechanical and other physical risks) of non-food consumer products (e.g. cosmetic products and their ingredients, toys, textiles, clothing, personal care and household products) and services (e.g. tattooing, artificial sun tanning).</p> <p>http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm</p>
2b Member of a Managing Body, Scientific Advisory Body or equivalent structure	2008-present	NanoSafe, meeting organised every 2 year by CEA (FR) and EU. First meeting ran from 3-7 Nov 2008	<p>Member of the International Scientific Committee.</p> <p>The objectives of the conference is to make available the major progresses and future trends in the domain of the safe production and use of nanomaterials.</p> <p>http://www.nanosafe.org/scripts/home/publigen/content/templates/show.asp?L=EN&P=55&vTicker=alleza</p>

3 RESEARCH SUPPORT

	<i>Within the past 5 years, have you, or the research entity to which you belong, received any support from a legal entity or other body with an interest in the field of activity of the Scientific Committees and their working groups in question?</i>	yes	no
--	---	------------	-----------

3a	Research support, including grants, rents, sponsorships, fellowships, non-monetary support	<input checked="" type="checkbox"/>	<input type="checkbox"/>
-----------	---	-------------------------------------	--------------------------

Activity	Time period (from... until month/year)	Name of legal entity or body	Description
Research grants and other funding	01/2009 - 12/2013	-Name: Fonds Wetenschappelijk Onderzoek – Vlaanderen (FWO)	<p>Mechanistic study of the toxic effects of ultra fine or nanoparticles. The role of inflammation on the translocation from the lung to the blood. Promotor 0% private funding</p> <p>The mechanisms of action of fine and ultrafine particles on the lung epithelium are not yet fully understood. In this project we seek to better understand what happens if particles reach deep into the lung and come in contact with the epithelium. We will concentrate on some strongly related processes: translocation, changes in the cell-layer, oxidative stress, pulmonary (and systemic)</p>

			inflammation.
	01/2008 – 12/2013	-Name: Fonds Wetenschappelijk Onderzoek – Vlaanderen (FWO)	<p>Mechanisms of the pulmonary and cardiovascular effects of particulate air pollution</p> <p>Co-Promotor 0% Private funding</p> <p>In vitro approach: To evaluate the interactions and contributions of different cell types, present in the lung, we performed independent cell cultures of epithelial cells (A549), macrophages (THP-1), mast cells (HMC-1) and endothelial cells (EAHY926), as well as co-cultures of selected combinations of these cells. The different cultures were exposed to particulate matter (PM10 and PM2.5) and supernatants were collected 24 h later for subsequent cytokine analysis</p> <p>in vivo approach To investigate the relationship between lung inflammation, systemic inflammation and activation of the coagulation cascade in mice.</p>
	01/2008 - 12/2013	-Name: Fonds Wetenschappelijk Onderzoek – Vlaanderen (FWO)	<p>Early biomarkers of chemical-induced asthma in mice and humans.</p> <p>Promotor 0% private funding</p> <p>Occupational asthma is the most common work-related lung disease in the industrial world and is responsible for 15 % of</p>

			<p>the adult asthma incidence.</p> <p>AIM</p> <p>A) Pathogenesis of (occupational) asthma – mechanisms and early biomarkers</p> <p>B) Translational research: investigation of the peptide and protein profile in sputum samples of patients with occupational asthma</p>
	05/2009 - 10/2012	Name: EU-project within KP7 - COOP	<p>ENPRA: Risk assessment of engineered nano particles.</p> <p>Co-promotor</p> <p>0% private funding</p> <p>The project is a major new European Framework 7 project to develop and implement a novel integrated approach for engineered nanoparticle (ENP) risk assessment.</p> <p>ENPRA will utilise the latest advances within in vitro, in vivo and in silico approaches to nanotechnology environment, health & safety (EHS) research to realise its aims. The in vitro and in silico approaches to be developed within ENPRA will help to reduce the need for animal experimentation in</p>

			nanotoxicology
	10/2007 - 09/2012	Name: KU Leuven internal funding - Bijzonder Onderzoeksfonds (BOF)	<p>Mechanisms of the pulmonary and cardiovascular effects of particulate air pollution Promotor 0% Private funding In general, the conceptual objective of the study is that pulmonary exposure to engineered nanoparticles (NPs) may induce systemic effects which are relevant to atherogenesis or the progression of atherosclerosis.</p> <p>The toxicological testing of NPs will include physico-chemical characterization of nanomaterials used, in vitro assays, and in vivo studies. All exposures will be performed using low concentrations of NPs and, when applicable, chronic exposure will be performed. In vitro studies in this project will focus on the mechanistic aspects of endothelial dysfunction upon pulmonary exposure.</p>
	01.01.2014 - 31.12.2017	Name: Fonds Wetenschappelijk	Transient Receptor Potential (TRP) Cation

		Onderzoek – Vlaanderen (FWO)	Channels as molecular targets of nanoparticles in the lung and airways.
	01.01.2013 - 31.12.2014	Stichting tegen Kanker, BE	Physicochemical properties of asbestos and carbon nanotubes associated to genetic and epigenetic effects. Preventing fibrous hazard by design.
	01.01.2015 - 31.12.2016	Stichting tegen Kanker, BE	Physicochemical properties of asbestos and carbon nanotubes associated to genetic and epigenetic effects. Preventing fibrous hazard by design.
	01.10.2015 - 31.09.2017	Respire 2 (European Respiratory society)	Detecting carbon nanotube (CNT) induced genetic and epigenetic alterations- establishing potential predictive biomarkers for human lung cancer risk.
	01/03/2016 - 01/03/2020	Belspo	To2DeNano: Towards a toxicologically-relevant definition of nanomaterials
	16/11/2016 - 16/11/2020	Taiwan ministry of education	Occupational sensitization to low-molecular-weight compounds. Relation between dermal and respiratory routes of sensitization and elicitation
	01/10/2016 - 30/09/2018	KU Leuven	Exposure assessment: from individual characterization to biomarkers discovery
	01/10/2013 - 30/09/2018	GOA – Ku Leuven	Neuro-immune mechanisms of visceral and airway hypersensitivity

4 FINANCIAL INTERESTS

	<i>Do you have current investments in a legal entity with an interest in the field of activity of the Scientific Committees and their working groups in question, including holding of stocks and shares, and which amounts to more than 10,000 EUR per legal entity or entitling you to a voting right of 5% or more in such legal entity?</i>	yes	no
--	---	------------	-----------

4a	Shares	<input type="checkbox"/>	<input checked="" type="checkbox"/>
4b	Other stock	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Investment	Name of legal entity	Description
		NO INTEREST TO DECLARE

5 INTELLECTUAL PROPERTY

	<i>Do you have any intellectual property rights that might be affected by the outcome of the work carried out by the Scientific Committees and their working groups in question?</i>	yes	no
--	--	------------	-----------

5a	Patent, trademarks, or copyrights	<input type="checkbox"/>	<input checked="" type="checkbox"/>
5b	Others	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Intellectual property	Description
	NO INTEREST TO DECLARE

6 PUBLIC STATEMENTS AND POSITIONS

8 OTHER RELEVANT INFORMATION

yes no

8a	<i>Are there any other elements that could be seen as undermining your independence when providing advice to the Commission in the field of activity of the Scientific Committees and their working groups in question?</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
-----------	---	--------------------------	-------------------------------------

Description:

I hereby declare on my honour that I have read the guidance for completing this form. I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge.

Should there be any change to the above information, including as regards upcoming activities, I will promptly notify the competent Commission department and complete a new DOI form describing the changes in question.

I am informed that my personal data are stored, processed and published by the Commission in accordance with Regulation (EC) N° 45/2001.

Date: 27 Jan 2018

Signature: _____



P Hoet

Your DOI form shall be made publicly available on the Register of Commission Expert Groups and Other Similar Entities, as long as you are appointed as member of the expert group or sub-group in a personal capacity. Technical measures will be taken to indicate to search engines that your DOI form should not appear in search results.